Ensysce Biosciences, Inc. (ENSC): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$7.93M

Year ended 2025-12-31

Period ended	Free Cash Flow	Change YoY	Source filing
2025-12-31	-$7.93M	n/a	2026-03-30, From 2025-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Free Cash Flow	Change YoY
Ensysce Biosciences, Inc. (ENSC)	2025-12-31	-$7.93M	n/a
ProPhase Labs, Inc. (PRPH)	2025-12-31	-$8.34M	n/m
China Pharma Holdings, Inc. (CPHI)	2025-12-31	$88.9K	n/m
Korro Bio, Inc. (KRRO)	2025-12-31	-$79.08M	n/m
Immunome Inc. (IMNM)	2025-12-31	-$200.60M	n/m
Whitehawk Therapeutics, Inc. (WHWK)	2025-12-31	-$97.98M	n/m
Ovid Therapeutics Inc. (OVID)	2025-12-31	-$38.33M	n/m
Camp4 Therapeutics Corp (CAMP)	2025-12-31	-$29.83M	n/m
Xenon Pharmaceuticals Inc. (XENE)	2025-12-31	-$279.92M	n/m

Compare ENSC, PRPH, CPHI, KRRO side by side · Screen every company in Pharmaceutical Preparations ↗